OncoResponse Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OncoResponse Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11025
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OncoResponse Inc (OncoResponse) focuses on the discovery, development and commercialization of therapeutic antibodies for the treatment of cancer. The company’s lead program includes ONCR-201, an anti-EMP2 fully-human monoclonal antibody, which is developed for female malignancies. It utilizes I-STAR platform, to interrogate the human memory B-cell repertoire of cancer patients. OncoResponse works in partnership with MD Anderson Cancer Center, Theraclone Sciences, Oregon Health & Science University to develop cancer therapeutics. It is funded by Canaan Partners, GreatPoint Ventures, and Helsinn Investment Fund among others. The company operates through a facility located in Seattle, Washington, the US. OncoResponse is headquartered in Houston, Texas, the US.

OncoResponse Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OncoResponse Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OncoResponse Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
OncoResponse Raises USD40 Million in Series B Financing 11
OncoResponse Raises Additional USD3 Million in Series A Financing 13
OncoResponse Raises Additional USD7 Million in Series A Financing 15
OncoResponse Raises USD9.5 Million in Series A Financing 16
OncoResponse Raises USD16.5 Million in Venture Financing 18
Partnerships 19
OncoResponse Enters into Agreement with OHSU Knight Cancer Institute 19
Equity Offering 20
Baxalta Invests in OncoResponse 20
Acquisition 21
OncoResponse Acquires Paganini Biopharma 21
OncoResponse Inc – Key Competitors 22
OncoResponse Inc – Key Employees 23
OncoResponse Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Corporate Communications 25
Jan 02, 2018: OncoResponse Expands Scientific Leadership With the Addition of Dr. Anil Singhal as CSO and Dr. Kamal D. Puri as VP, R&D 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
OncoResponse Inc, Pharmaceuticals & Healthcare, Key Facts 2
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OncoResponse Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OncoResponse Inc, Deals By Therapy Area, 2012 to YTD 2018 8
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
OncoResponse Raises USD40 Million in Series B Financing 11
OncoResponse Raises Additional USD3 Million in Series A Financing 13
OncoResponse Raises Additional USD7 Million in Series A Financing 15
OncoResponse Raises USD9.5 Million in Series A Financing 16
OncoResponse Raises USD16.5 Million in Venture Financing 18
OncoResponse Enters into Agreement with OHSU Knight Cancer Institute 19
Baxalta Invests in OncoResponse 20
OncoResponse Acquires Paganini Biopharma 21
OncoResponse Inc, Key Competitors 22
OncoResponse Inc, Key Employees 23
OncoResponse Inc, Other Locations 24
OncoResponse Inc, Subsidiaries 24

List of Figures
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
OncoResponse Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[OncoResponse Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Quorum Business Solutions Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Quorum Business Solutions Inc (QBS) is a technology company that develops, implements, and supports software solutions. The company offers software in the areas of accounting; transactions and logistics management; land, property and right of way management; liquid and gas measurement; energ …
  • Northland Power Inc (NPI):電力:M&Aディール及び事業提携情報
    Summary Northland Power Inc. (Northland Power) is an independent power producer that develops, finances, builds, owns, and operates clean and green power projects in Canada and internationally. The company generates energy from natural gas, biomass, landfill gas, wind and solar sources. In thermal g …
  • China Vanke Co., Ltd.:企業の戦略・SWOT・財務情報
    China Vanke Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary China Vanke Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Pioneer Corporation (6773):企業の財務・戦略的SWOT分析
    Pioneer Corporation (6773) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Microchip Technology Incorporated (MCHP):企業の財務・戦略的SWOT分析
    Microchip Technology Incorporated (MCHP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • DNO ASA (DNO):石油・ガス:M&Aディール及び事業提携情報
    Summary DNO ASA (DNO) is an oil and gas company that provides mineral properties exploration and development services. The company's services include selective and targeted drilling, fractured carbonate plays that are characteristic of the MENA region. It also provides operations in petroleum, shipp …
  • Alliqua BioMedical Inc (ALQA)-製薬・医療分野:企業M&A・提携分析
    Summary Alliqua BioMedical Inc (Alliqua BioMedical), formerly HepaLife Technologies Inc is a regenerative technology company that builds a suite of regenerative solutions for wound and tissue repair. The company’s product categories include ultrasound healing therapy, human biologics, antimicrobial …
  • Feintool International Holding AG (FTON):企業の財務・戦略的SWOT分析
    Feintool International Holding AG (FTON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Vestagen Protective Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Vestagen Protective Technologies Inc (Vestagen), formerly Vestagen Technical Textiles Inc, is a medical technology company. The company develops, manufactures and markets textile products and technologies for uniforms and other apparel for specialty healthcare workers, patients and other occ …
  • HD Supply Holdings, Inc.:企業の戦略・SWOT・財務情報
    HD Supply Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary HD Supply Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • AltaGas Ltd.:企業の戦略・SWOT・財務分析
    AltaGas Ltd. - Strategy, SWOT and Corporate Finance Report Summary AltaGas Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Obuv Rossii OOO (OBUV):企業の財務・戦略的SWOT分析
    Obuv Rossii OOO (OBUV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Indigo Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Indigo Biosciences Inc (Indigo) is a provider of preclinical contract research services. The company’s products include assay kit platforms and formats, nuclear receptor, signaling pathway, and cell viability assay products, mitochondrial function products, and luciferase detection reagents. …
  • Puget Sound Energy Inc:電力:M&Aディール及び事業提携情報
    Summary Puget Sound Energy Inc (PSE), a subsidiary of Puget Energy Inc, is a utility service provider. The company offers offers services such as energy and natural gas supply, start service, power outages, natural gas safety, business services, natural gas storage and excess generation of energy. I …
  • SolarCity Corporation-エネルギー分野:企業M&A・提携分析
    Summary SolarCity Corporation (SolarCity), a subsidiary of Tesla, Inc., is a vertically integrated solar energy systems provider that designs, permits, finances, and installs the solar energy and storage systems,. The company also performs maintenance and monitoring services. It procures various com …
  • Par Pacific Holdings Inc (PARR):企業の財務・戦略的SWOT分析
    Par Pacific Holdings Inc (PARR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • ReproCELL Inc (4978):製薬・医療:M&Aディール及び事業提携情報
    Summary ReproCELL Inc (ReproCELL) is a biotechnology company that develops and commercializes stem cell technologies. The company offers products in divisions such as research reagents, cultivation materials, and cell and biorepository. Its research reagent products include hES iPSC culture reagents …
  • Pacific World Corporation:企業の戦略・SWOT・財務情報
    Pacific World Corporation - Strategy, SWOT and Corporate Finance Report Summary Pacific World Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • NewMarket Corp (NEU):企業の財務・戦略的SWOT分析
    NewMarket Corp (NEU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • XERIS Pharmaceuticals Inc (XERS):医療機器:M&Aディール及び事業提携情報
    Summary XERIS Pharmaceuticals Inc (XERIS) is a specialty pharmaceutical company that develops and commercializes injectable and infusible drug formulations. The company’s proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of ultra concentr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆